Summary
Serum CA15-3, CEA, and BCA225 concentrations were determined in 98 patients with advanced or recurrent breast cancer in an attempt to correlate elevation with clinical status. The rate of serum positivity was 68.4% (67/98), 55.1% (54/98), and 43.9% (43/98) for CA15-3, CEA, and BCA225, respectively. After a 4 weeksinterval, a 20% change of tumor marker concentration from the preceding assay correlated significantly with clinical findings. Significant elevation was predictive of new recurrence or tumor regrowth after complete remission, especially in patients with bone metastasis. The 20% change in concentration at 4 weeks was also useful in patients with tumor marker concentrations persistently beneath the cut-off level for positive. Serological evaluation of tumor markers in patients with advanced or recurrent breast cancer should seek to document 20% changes over a 4 week interval.
Article PDF
Avoid common mistakes on your manuscript.
References
Kobayashi S, Iwase H: Prognostic factors and evaluation of effect in drug therapy of breast cancer. Excepta Medica, International Congress Series 945, 1990, pp 183–190
Iwase H, Kobayashi S: Evaluation of effects of breast cancer treatments by serum tumor marker. Jpn J Breast Cancer 7: 356–365, 1992 (in Japanese)
Kobayashi S, Iwase H, Karamatsu S, Matsuo K, Masaoka A, Miyagawa T: The clinical value of serum CA15-3 assay postoperatively in breast cancer patients. Jpn J Surg 19: 278–282, 1989
Colomer R, Ruibal A, Genolla J, Rubio D, DelCampo JM, Bodi R, Salvador L: Circulating CA15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Research and Treatment 13: 123–133, 1989
Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674–1681, 1989
Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A, Bruscagnin G: The tumour associated antigen CA15-3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 63: 809–813, 1991
Duncan JL, Price A, Rogers K: The use of CA15-3 as a serum tumor marker in breast carcinoma. Eur J Surg Oncol 17: 16–19, 1991
Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA, Schwartz DC: CA15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clinica Chimica Acta 200: 81–94, 1991
Mesa-Tejada R, Palakodety RB, Leon JA, Khatcherian AO, Greaton CJ: Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. American Journal of Pathology 130: 305–314, 1988
Hirohashi S, Watanabe M, Shimosato Y: Monoclonal antibody reactive with the sialyl-sugar residue of a high molecular weight glycoprotein in sera of cancer patient. Jpn J Cancer Res 75: 485–488, 1985
Mobus V, Paula J, Beck T, Crombach G, Kreienberg R: Tumour Marker Courses to assess the efficacy of chemotherapy or hormone therapy in metastasising breast cancer. Geburtsh u Frauenheilk 53: 24–29, 1993 (in German)
Ohkura H, Sugano Y, Shimada Y, Saitou D, Shirao K, Okazaki N, Okada S, Yoshimori M: Evaluation of cancer treatment by serum markers. J Clin Surg 47: 6231–628, 1992 (in Japanese)
Staab HJ: Slope analysis of the postoperative CEA time course and possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg 136: 322–327, 1978
Author information
Authors and Affiliations
Additional information
The cooperative group is organized from Surgery departments of Ena Byoin National Sanatorium, director Tetsuo Hotta; National Health Insurance Sakishima Hospital, Tsutoh Niwa; Nagoya City Johoku Hospital, director Hiroshi Itoh; Toyokawa City Hospital, director Kazuo Shibata; Nagoya City Higashi Hospital, director Hironori Tanaka; Toyota Memorial Hospital, director Shoji Karamatsu; Nagoya City Johsai Hospital, director Katsumi Nakamae; Sakuragaoka Branch Toyohashi Municipal Hospital, director Koji Matsuo; National Health Insurance Kamiyahagi Hospital, director Kaoru Kondo
Rights and permissions
About this article
Cite this article
Iwase, H., Kobayashi, S., Itoh, Y. et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Tr 33, 83–88 (1995). https://doi.org/10.1007/BF00666074
Issue Date:
DOI: https://doi.org/10.1007/BF00666074